Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Priority review for Keytruda in head and neck cancer

FDA assessment raises prospect of third indication for Merck & Co's immuno-oncology drug

- PMLiVE

Novartis kicks back against US corruption charges

Investigation ‘explodes’ with US government information request on 79,000 physicians events

Gilead Sciences

Gilead must pay just $200m for hep C patents, says jury

Merck & Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

- PMLiVE

Sanofi and Merck & Co dissolve longstanding vaccines alliance

Lacklustre sales at Sanofi Pasteur MSD prompts split

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

Novartis building

Novartis claims FDA breakthrough status for leukaemia treatment

Designation could speed up development and access for Novartis’ PKC412

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links